The Tat protein encoded by human immuno deficiency virus tpe 1 is a strong ranscriptional activator of gene expression from the viral long terminal repeat and is essential for virus replication. We have investigated the molecular m anism of Tat trans-activation by using a cell-free transcription system. We find that the trans-activation domain of Tat, amino acid residues 1-48 [Tat-(1-48)J, can inhibit specifically-i.e., "squelch," transcriptional activation by fulllength Tat . Squelching depends upon the functional integrity of the Tat trans-activation domain because the mutant , which is defective in Tat trans-activation in vivo and in vitro, does not squelch in vitro Tat transactivation. Inhibition is selective because Tat-activated transcription, but not Tat-independent tnscription, is squelched. Preincubation experiments with Tat or Tat-(1-48) and nuclear extracts show that the trans-activation region of Tat can interact with cellular coactivator(s) required for Tat trans-activation and that this interaction can occur in the absence of the human inmunodeficiency virus long terminal repeat promoter. Furthermore, the putative coactivator(s) mediating trans-activation by Tat differ from those mediating trans-activation by the acidic activator VP16, as shown by reciprocal squelching experiments in vitro. Our results suggest that specific cellular coactivator(s) are required for medfaing activated transcription by human immunodefidency virus type 1 Tat.
[AlaflJTat- , which is defective in Tat trans-activation in vivo and in vitro, does not squelch in vitro Tat transactivation. Inhibition is selective because Tat-activated transcription, but not Tat-independent tnscription, is squelched. Preincubation experiments with Tat or Tat-(1-48) and nuclear extracts show that the trans-activation region of Tat can interact with cellular coactivator(s) required for Tat trans-activation and that this interaction can occur in the absence of the human inmunodeficiency virus long terminal repeat promoter. Furthermore, the putative coactivator(s) mediating trans-activation by Tat differ from those mediating trans-activation by the acidic activator VP16, as shown by reciprocal squelching experiments in vitro. Our results suggest that specific cellular coactivator(s) are required for medfaing activated transcription by human immunodefidency virus type 1 Tat.
Human immunodeficiency virus type 1 (HIV-1) Tat strongly activates gene expression from the HI'V-1 long terminal repeat (LTR) through the trans-activation response region (TAR) located immediately downstream of the initiation site (for review, see ref. 1) . Based on genetic analysis, a cofactor, presumably an unidentified transcription factor, has been proposed to be required for Tat trans-activation (refs. 2 and 3; for review, see ref. 4 ). Additionally, human-specific factors encoded by chromosome 12 were required for Tat-mediated trans-activation in rodent cells (5, 6) . Candidate cellular proteins have been identified. These proteins include TAP (Tat-associated protein) (7) and transcription factor Spl (8) , which have been shown to bind Tat in solution assays, as well as Tat-binding protein 1 (9) and the mammalian suppressor of sgvl (MSS1) protein (10) , for which direct binding to Tat has not been demonstrated. The functions of these candidate Tat-binding proteins in Tat-mediated transcriptional activation remain to be established.
Transcriptional activators such as Tat are thought to function by interacting with components ofthe basic transcription machinery (for review, see ref. 11) . Because initiation of transcription by RNA polymerase II requires the ordered assembly of general factors (TFII-A, -B, -D, -E, -F, and -H) and RNA polymerase II, any one ofthese factors could be the target of an activator. Different classes of trans-activators may interact with the general transcription apparatus by different mechanisms. (i) They may directly contact general transcription factors (12) (13) (14) (15) (16) (17) (18) . (ii) A new class of factor, termed coactivator, adaptor, or mediator, may bridge the activator to the general transcriptional apparatus (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . (iii) The transcriptional activation process may be more complex and involve multiple contacts between activator, coactivator, and general transcriptional factors (30) .
Because of our interest in host-cell factors involved in Tat-mediated trans-activation, we have developed an in vitro "squelching" assay that responds to the Tat trans-activation region Tat-(1-48) (31, 32 
MATERIALS AND METHODS
Plasmids. The adenovirus type 2 maor late promoter (MLP)-chloramphenicol acetyltransferase (CAT) (33), pCD23 (HIV-LTR-CAT), which contains the HIV LTR sequence from -117 to +80 upstream of CAT gene (34) , pHIV-TAR(+), and pHIV-TAR(+35/+38) (35) were used as templates for in vitro transcription. pQTat-6His, which expresses a Tat-(1-86) fusion protein containing six histidine residues at its C terminus, was constructed as described (Li Yu, P.M.L., Zhenhua Zhang, and M.G., unpublished data). pGEX-KG- Tat41-48) and pGEX-KG-[Ala4eTat- were grown to an absorbance of 0.6 at 600 nm and induced with 0.5 mM isopropyl ,3-D-thiogalactoside. After 3 hr, cells were harvested by centrifugation, resuspended in 1/40th the culture volume of RS buffer (20 mM Hepes, pH 7.9/0.2 mM EDTA/1 M NaCl/1 mM dithiothreitol/l mM phenylmethylsulfonyl fluoride), and lysed by sonication in an ice bath. Cell debris was removed by centrifugation, and the supernatant was incubated with preswollen glutathione-agarose beads at 40C for 1 hr. Beads were collected by centrifugation at 1000 x g for 1 min, washed with RS buffer, and stored at 40C. The glutathione S-transferase (GST)-Tat fusion proteins were eluted from the beads with 50 mM reduced glutathione, pH 8.0. For some applications, Tat proteins were cleaved from the beads with thrombin (36) . Purified GAL4-VP16 protein used in transcription reactions was provided by S. Roberts and M. R. Green, University of Massachusetts Medical Center. The purity and concentration of the fusion proteins were determined by SDS/PAGE and Coomassie blue staining using bovine serum albumin as a standard.
In Vitro Transcription Reactions. HeLa nuclear extracts were prepared by the procedure of Dignam et al. (38) as described (39) . In vitro Tat trans-activation reactions (25 IlI) analyzed by run-off assay contained 12 mM Hepes (pH 7.9); 4 mM creatine phosphate; 0.1 mM EDTA; 10 mM MgCl2; 0.7 mM dithiothreitol; 60mM KCl; 8% (vol/vol) glycerol; 500 ,uM ATP, CTP, and GTP; 25 ,uM UTP; 5 mCi of [a-32P]UTP (1 Ci = 37 GBq); 6mM sodium citrate (40); 500 ng oftemplate DNA; 20 units of placental RNase inhibitor (Boehringer Mannheim); and 10 pI of HeLa nuclear extract. As templates, pHIV-TAR(+) was linearized with EcoRI or BamHI to yield run-off transcripts of =1000 and 800 nt, respectively. Transcripts of uncut MLP-CAT, HIV-LTR-CAT, and pG5E1bCAT templates were analyzed by primer extension. The reaction mixture described for run-off assay was modified to contain 500 pM of the four NTPs, no labeled precursor, and no sodium citrate. RNA transcripts were isolated by phenol-chloroform extraction, ethanol precipitation, and hybridized at 65°C for 20 min with 50 fmol of the 5'-end-labeled 31-mer CAT primer (41) in 11 /4 of a buffer containing 50 mM Tris (pH 8.3), 50 mM KCl, 10 mM MgCl2, 10 mM dithiothreitol, 1 mM spermidine, and 1 mM each of the four dNTPs. The reverse transcription reaction was initiated by the addition of 9 4 of solution containing 50 mM Tris (pH 8.3), 50 mM KCl, 10 mM MgCl2, 10 mM dithiothreitol, 1 mM of each dNTP, 1 mM spermidine, 6 mM sodium pyrophosphate, 2.5 units of avian myeloblastosis virus reverse transcriptase (Promega) followed by incubation at 42°C for 30 min. The primer-extension products and run-off transcripts were analyzed by denaturing PAGE and visualized by autoradiography.
RESULTS
The Tat Trans-Activation Domain Tat-(1-48) But Not the
Squelch Specifically Tat Trans-Activation in Vitro. To investigate the molecular mechanism of Tat transactivation, we have used an in vitro trans-activation system containing 6 mM sodium citrate, which suppresses basal level transcription (40) . The addition of 100 ng of recombinant Tat-(1-86) purified to near homogeneity (data not shown) strongly stimulated transcription from the HIV-1 LTR promoter. Correct initiation of transcription was established by run-off analysis using as templates pHIV-TAR(+) linearized with either EcoRI orBamHI, which produces transcripts of =1000 and 800 nt, respectively (Fig. 1) . Tat trans-activation is authentically TAR-dependent because the TAR-defective mutant pHIV-TAR(+35/+38) (35) , which contains a deletion (35, 43, 44) . When increased amounts of Tat-(1-48) were included in the in vitro transcription reaction containing Tat-(1-86) (100 ng), trans-activation was strongly squelched (Fig. 2A ). In contrast, the same concentrations of the mutant protein, [Ala4e]Tat-(1-48), did not affect Tat trans-activation (Fig.   2B ). Similar results were obtained when the experiments of Fig. 2 A and B were repeated using GST-Tat-(1-48) and GST-[Ala4iTat-(1-48) (data not shown). The GST-Tat-(1-48) fusion protein was found as effective as Tat-(1-48) on a molar level and used in subsequent experiments.
We next determined the minimum concentration of GSTTat-(1-48) needed for squelching. Fig. 2C shows that Tat trans-activation was significantly squelched by 50 ng of Tat-(1-48) and completely squelched by 100-400 ng. These results suggest a functional correlation between transactivation and squelching and support the hypothesis that high levels of the Tat activation region sequester cofactor(s) required for Tat trans-activation of the HIV LTR promoter.
Tat-Activated Transcription, But Not Tat-Independent (Fig. 3) . The highest concentration of Tat-(1-48) used in these reactions (1600 ng, Fig. 3 ) was >30-fold higher than needed to squelch significantly Tat-(1-86)-activated transcription (see Fig. 2C ). In addition, run-off experiments with HIV TAR(+) as template in the absence of Tat-(1-86) and sodium citrate also showed no inhibition of Tat-independent transcription by addition of 1600 ng of Tat Fig. 4 shows that preincubation of Tat-(1-86) with extract for 30 min rendered Tat trans-activation resistant to squelching by subsequent addition of Tat-(1-48) (Fig. 4, lanes 4) . On the other hand, preincubation of the extract with Tat-(1-48) blocked transactivation by subsequent addition of Tat-(1-86) (Fig. 4, lanes  3) . Fig. 4A also shows that the HIV-LTR promoter is dispensable for the interaction between Tat and its putative coactivator(s), although inclusion of HIV-1 LTR promoter in the preincubation reaction somewhat increased the overall transcription level. Most important, preincubation of [Ala41Tat-(1-48), in lieu of Tat-(1-48), with the nuclear extract showed no effect on Tat-(1-86) trans-activation (Fig.  4B, compare lanes 3 and 5) . These results lend further support to the conclusion that the Tat activation domain interacts with a transcriptional coactivator(s) required for Tatmediated trans-activation. The Coactivator(s) Required for Tat Trans-Activation Differ from Those Required for Function of an Acidic Activator. To address the question of whether coactivator(s) required for Tat trans-activation are common to other trans-activators, we examined the well-studied GAL4-VP16-dependent in vitro transcription system. The chimeric trans-activator GAL4-VP16, which contains the DNA-binding domain of GAL4 and the potent acidic activating domain of VP16, strongly stimulated transcription from pG5E1bCAT, which contains a core promoter (adenovirus Elb TATA box) and five upstream GALA-binding sites (Fig. 5A, lanes 1 and 2) . In agreement with previous studies (21, 23, 25) , high levels of GAL4-VP16 decreased transcriptional activation due to selfsquelching (compare Fig. SA, lanes 2 with lanes 3 and 4) . If the acidic activating domain of VP16 and the activation domain of Tat use the same coactivator(s), one would anticipate reciprocal inhibition of trans-activation by high concentrations of either trans-activator. Fig. 5B shows that Tat-(1-48) did not inhibit trans-activation by GAL4-VP16, even when 2400 ng was added to the reaction mixture, 50-fold higher than that needed for significant inhibition ofTat-(1-86) trans-activation (see Fig. 2C ). To exclude the possibility that the lack of squelching may be due to a much higher affinity (1-48) (100 ng), and/or pHIV-TAR(+) was done at 30"C for 30 min ('). Tat-(1-86) or Tat-(1-48), with or without pHIV-TAR(+), was then added as indicated together with ribonucleoside triphosphates (NTPs) followed by incubation at 300C for 60 min ('), and run-off transcription assays were done. In A, lanes 1-4 were exposed for 6 hr, and lanes 5-8 were exposed for 12 hr. In B, exposure was for 12 hr.
ofVP16 than Tat-(1-48) for the coactivator(s), we determined whether GAL4-VP16 can inhibit Tat trans-activation. As shown in Fig. 5C , GAL4-VP16, at a concentration that significantly exhibited self-squelching, did not inhibit transcriptional activation by Tat. These results support the conclusion that distinct coactivators mediate trans-activation by Tat and the acidic activator VP16.
DISCUSSION
We have developed an in vitro squelching assay that responds to the Tat activation region, Tat-(1-48). activation domain, Tat-(1-48), which is used to squelch Tat trans-activation, does not inhibit basal transcription of the LTR or MLP at 1600 ng per reaction. Thus, the transcriptional squelching measured in our assays is not the nonspecific inhibition seen with high levels offull-length Tat- .
Using an in vitro trans-activation assay driven by noninhibitory levels of Tat-(1-86), we first showed that the region necessary for inhibition of activated transcription resides in Tat amino acid residues 1-48. By using the mutant [Ala4]Tat- both of these mutants were unable to squelch (data not shown). By monitoring Tat-independent transcription from both HIV-1 LTR and adenovirus type 2 MLP promoters, we find that squelching exerted by high levels of the Tat activation domain is specific for Tat-activated transcription and that Tat-independent transcription is unaffected. Based on these combined results we suggest that the Tat activation region, when present at high concentration, sequesters a cellular target(s) required for Tat trans-activation and thereby squelches transcriptional activation by full-length Tat.
We next used a preincubation strategy to obtain more direct evidence for the existence of a coactivator(s) required for Tat transcriptional activation. We preincubated the activator Tat-(1-86) or the competitor Tat-(1-48) with the nuclear transcription extract to permit prior formation of an activatorcoactivator or a competitor-coactivator complex. After pre- (Fig. 4) . The interaction between Tat and its coactivator can occur in the absence of a DNA template.
To characterize further the putative Tat-responsive coactivator(s), we asked whether it was also required for transactivation by an acidic activator, VP16. If Tat and VP16 use a common coactivator for trans-activation, we should observe reciprocal squelching. In agreement with previous reports, high concentration of GAL4-VP16 squelched GAL4-VP16-dependent trans-activation. However, no squelching of GAL4-VP16 trans-activation was observed by the Tat trans-activating domain and vice versa. These results indicate that coactivators required for mediating transactivation by Tat are distinct from those required for the acidic activator VP16.
On the basis of the biochemical results presented here and previous genetic studies on Tat trans-activation (2, 3), we propose that Tat-specific coactivator(s) are required for Tat-activated transcription. Elucidation of the exact roles played by coactivator(s) in Tat transcriptional activatione.g., initiation, elongation, or facilitation of Tat-TAR interaction-will provide further insight into the molecular mechanisms governing the regulation of HIV-1 gene expression. Our data that the interaction between Tat and its coactivator(s) can occur in solution and the assay system we have developed should facilitate biochemical approaches to the purification and cloning of the Tat-specific cellular coactivator(s). We have recently obtained evidence that the ultimate cellular target of transcriptional squelching by Tat-(1-48) is the basal transcription factor TFIIB. This is of great interest because TFIIB has been shown to be recruited to the transcription initiation complex by three classes of transcriptional activators (30) . However, TFIIB does not bind directly to Tat-(1-48) (our unpublished data), thus implicating an intermediate between Tat and TFIIB. Workers in our laboratory have identified a candidate cellular protein, TAP (Tat-associated protein) which strongly and specifically binds to both Tat and TFIIB (ref. 7; Li Xu, P.M.L., Zhenhua Zhang, and M.G., unpublished work). We speculate that TAP may serve as an adaptor/coactivator that links Tat to the transcription machinery via TFIIB.
